Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
2.300
+0.010 (0.44%)
At close: Oct 28, 2025, 4:00 PM EDT
2.350
+0.050 (2.17%)
After-hours: Oct 28, 2025, 7:59 PM EDT
Cardiff Oncology Employees
As of December 31, 2024, Cardiff Oncology had 33 total employees, including 32 full-time and 1 part-time employees. The number of employees increased by 1 or 3.13% compared to the previous year.
Employees
33
Change (1Y)
1
Growth (1Y)
3.13%
Revenue / Employee
$16,515
Profits / Employee
-$1,546,758
Market Cap
153.01M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 33 | 1 | 3.13% |
| Dec 31, 2023 | 32 | 6 | 23.08% |
| Dec 31, 2022 | 26 | 3 | 13.04% |
| Dec 31, 2021 | 23 | 11 | 91.67% |
| Dec 31, 2020 | 12 | -2 | -14.29% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CRDF News
- 3 days ago - Cardiff Oncology: Preparing For A Defining 2026 - Seeking Alpha
- 6 days ago - Cardiff Oncology's Promising Cancer Breakthrough Ahead - Why I Choose To Buy - Seeking Alpha
- 26 days ago - Cardiff Oncology to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Cardiff Oncology to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data? - Benzinga
- 3 months ago - Cardiff Oncology: Data Update Resolves Some Signals - Seeking Alpha
- 3 months ago - Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004) - GlobeNewsWire
- 4 months ago - Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity - Seeking Alpha